QS Investors’s Bio-Rad Laboratories Class A BIO Stock Holding History

QS Investors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$10.5M	Buy	16,363 +4,360	+36%	+$2.65M	0.12%	124
2021 Q1	$6.86M	Buy	12,003 +3,280	+38%	+$1.94M	0.08%	193
2020 Q4	$5.08M	Buy	8,723 +8,069	+1,234%	+$4.6M	0.06%	222
2020 Q3	$338K	Hold	654	–	–	﹤0.01%	877
2020 Q2	$296K	Buy	654 +54	+9%	+$23.8K	﹤0.01%	1041
2020 Q1	$211K	Hold	600	–	–	﹤0.01%	1046
2019 Q4	$224K	Hold	600	–	–	﹤0.01%	1157
2019 Q3	$200K	Hold	600	–	–	﹤0.01%	1203
2019 Q2	$188K	Hold	600	–	–	﹤0.01%	1235
2019 Q1	$184K	Sell	600 -407	-40%	-$110K	﹤0.01%	1248
2018 Q4	$234K	Hold	1,007	–	–	﹤0.01%	1090
2018 Q3	$315K	Hold	1,007	–	–	﹤0.01%	1076
2018 Q2	$291K	Hold	1,007	–	–	﹤0.01%	1086
2018 Q1	$252K	Hold	1,007	–	–	﹤0.01%	1101
2017 Q4	$240K	Hold	1,007	–	–	﹤0.01%	1138
2017 Q3	$224K	Hold	1,007	–	–	﹤0.01%	1177
2017 Q2	$228K	Hold	1,007	–	–	﹤0.01%	1158
2017 Q1	$201K	Buy	1,007 +1,000	+14,286%	+$193K	﹤0.01%	1229
2016 Q4	$1K	Hold	7	–	–	﹤0.01%	1541
2016 Q3	$1K	Hold	7	–	–	﹤0.01%	1528
2016 Q2	$1K	Buy	7 +2	+40%	+$285	﹤0.01%	1552
2016 Q1	$1K	Hold	5	–	–	﹤0.01%	1546
2015 Q4	$1K	Buy	+5	New	+$693	﹤0.01%	1562

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QS Investors's BIO Position: Q2 2021 in Review

QS Investors increased its Bio-Rad Laboratories Class A (BIO) stake by 36% in Q2 2021, buying an estimated $2.65M and bringing the position to 16,363 shares worth $10.5M. The position accounts for 0.12% of the portfolio, ranked #124.

QS Investors first reported a position in BIO in Q4 2015 and has held it in 23 quarters since. 508 funds tracked by Wall St. Rank hold BIO as of Q2 2021.

QS Investors held 16,363 shares of Bio-Rad Laboratories Class A worth $10.5M as of Q2 2021.
QS Investors bought 4,360 Bio-Rad Laboratories Class A shares in Q2 2021, an estimated $2.65M.
Bio-Rad Laboratories Class A made up 0.12% of QS Investors's portfolio in Q2 2021, its #124 holding.
QS Investors first reported a position in Bio-Rad Laboratories Class A in Q4 2015 and has held it in 23 quarters since.
508 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.